Abstract
Purpose
To report a case of juxtafoveal choroidal neovascularization in a patient with candida chorioretinitis successfully treated with intravitreal bevacizumab.
Methods
Case report.
Results
A 45-year-old woman previously treated for candida chorioretinitis was presented with reduced vision in the left eye. The patient was investigated with ophthalmoscopy, fluorescein angiography, and optical coherence tomography (OCT). Following initial treatment, fundus examination, fluorescein angiography, and OCT of the right eye revealed a secondary juxtafoveal classic choroidal neovascularization. Following a single intravitreal injection of bevacizumab, the patient had excellent visual recovery, with absence of subretinal or intraretinal fluid in the OCT.
Conclusions
Bevacizumab was effective in treatment of choroidal neovascularization associated with candida chorioretinitis.
References
Lashof AMO, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, Oborska IT, Rex JH, Kullberg BJ (2011) Ocular manifestations of candidemia. Clin Infect Dis 53(3):262–268. doi:10.1093/cid/cir355
Shah CP, McKey J, Spirn MJ, Maguire J (2008) Ocular candidiasis: a review. Br J Ophthalmol 92(4):466–468. doi:10.1136/bjo.2007.133405
Jampol LM, Sung J, Walker JD, Folk JC, Townsend-Pico WA, Lowder CY, Dodds EM, Westrich D, Terry J (1996) Choroidal neovascularization secondary to Candida albicans chorioretinitis. Am J Ophthalmol 121(6):643–649
Macular Photocoagulation Study Group (1994) Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol 112(4):500–509
Tedeschi M, Varano M, Lomoriello DS, Scassa C, Parisi V (2007) Photodynamic therapy outcomes in a case of macular choroidal neovascularization secondary to Candida endophthalmitis. Eur J Ophthalmol 17(1):124–127
Recchia FM, Shah GK, Eagle RC, Sivalingam A, Fischer DH (2002) Visual and anatomical outcome following submacular surgery for choroidal neovascularization secondary to Candida endophthalmitis. Retina 22(3):323–329
Durand ML (2013) Endophthalmitis. Clin Microbiol Infect 19(3):227–234. doi:10.1111/1469-0691.12118
Sallam A, Taylor SR, Khan A, McCluskey P, Lynn WA, Manku K, Pacheco PA, Lightman S (2012) Factors determining visual outcome in endogenous Candida endophthalmitis. Retina 32(6):1129–1134. doi:10.1097/IAE.0b013e31822d3a34
Doan T, Vemulakonda GA, Choi D, Keene CD, Akileswaran L, Van Gelder RN, Chao JR (2014) Retinal neovascularization and endogenous fungal endophthalmitis in intravenous drug users. Ophthalmology 121(9):1847–1848. doi:10.1016/j.ophtha.2014.03.037
Dhingra N, Kelly S, Majid MA, Bailey CB, Dick AD (2010) Inflammatory choroidal neovascular membrane in posterior uveitis-pathogenesis and treatment. Indian J Ophthalmol 58(1):3–10. doi:10.4103/0301-4738.58467
Coats ML, Peyman GA (1992) Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis. Retina 12(1):46–51
Shimada H, Yuzawa M, Hirose T, Nakashizuka H, Hattori T, Kazato Y (2008) Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy. Jpn J Ophthalmol 52(4):282–288. doi:10.1007/s10384-008-0566-2
Carreno E, Moutray T, Fotis K, Lee RW, Dick AD, Ross AH, Bailey C (2015) Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes. Br J Ophthalmol. doi:10.1136/bjophthalmol-2015-307806
Tian JX, O’Hagan S (2015) Toxocara polymerase chain reaction on ocular fluids in bilateral granulomatous chorioretinitis. Int Med Case Rep J 8:107–110. doi:10.2147/IMCRJ.S84185
Lyall DA, Hutchison BM, Gaskell A, Varikkara M (2010) Intravitreal ranibizumab in the treatment of choroidal neovascularisation secondary to ocular toxocariasis in a 13-year-old boy. Eye (Lond) 24(11):1730–1731. doi:10.1038/eye.2010.131
Kianersi F, Naderi Beni A, Naderi Beni Z, Ghanbari H (2015) Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to toxoplasmic retinochoroiditis: a case series. Semin Ophthalmol 30(3):181–187. doi:10.3109/08820538.2013.838278
Sheu SJ (2009) Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to endogenous endophthalmitis. Kaohsiung J Med Sci 25(11):617–621. doi:10.1016/S1607-551X(09)70566-2
Acknowledgements
RWJL and ADD received funding from the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None of the authors have any proprietary interest in the materials described in this study.
Ethical standard
This report is limited to secondary use of information previously collected in the course of normal care (without an intention to use it for research at the time of collection) and therefore excluded from REC review.
Rights and permissions
About this article
Cite this article
Makragiannis, G., Vahdani, K., Carreño, E. et al. Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis. Int Ophthalmol 38, 781–785 (2018). https://doi.org/10.1007/s10792-017-0502-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-017-0502-x